The aim of the present study was to investigate the relationship between the expression of iNOS, COX-2 and VEGF mRNA levels and malignancy degree in canine malignant mammary tumours. Thirty-five bitches presented with the complaint of mammary masses, aged 6-10 years and representing different breeds, were used. The expressions of iNOS, COX-2 and VEGF mRNA levels were significantly higher in both benign and malignant tumours than in the adjacent nonneoplastic mammary glands (P < 0.05). The iNOS, COX-2 and VEGF mRNA expression levels of grade 2 tumours were higher than those of grade 1 tumours; however, the highest expression levels were detected in grade 3 tumours. Thus, increased iNOS, COX-2 and VEGF gene mRNA levels were found to be related with the histological grade of malignancy in dogs with mammary tumours.
sions with those in clinically healthy mammary glands on the same mammary chain. To the best of our knowledge, this is the first study on the relationship between the expression of iNOS and malignancy degree in canine malignant mammary tumours.
Materials and methods

Animals
A total of 35 bitches (aged 6-10 years and representing different breeds) brought to the Clinic of Obstetrics and Gynaecology, Veterinary Faculty of the University of Ankara and University of Ondokuz Mayis with the complaint of mammary masses were used in the study. Animals with distant metastases and suspected inflammatory mammary carcinomas were not included. The surgical techniques included regional mastectomy as well as unilateral or bilateral complete mastectomy depending on the clinical stage and the number of tumours in the mammary gland chain. Malignant tumours were compared with adjacent non-neoplastic mammary glands of the dogs (NMGs) (n = 8). The study was performed according to the principles outlined in Decision No. 2014/8 of the Ethics Committee of Animal Research of Turkey.
Clinical and histopathological analysis
Before starting the study, a complete physical examination was done for all animals. All mammary glands and regional lymph nodes (axillary and inguinal) were examined. Thoracic radiographs (right and left lateral, ventrodorsal) were taken and abdominal ultrasonographic examination was performed to determine the presence of metastasis. In addition, the number of tumours per animal, location, adherence to skin, adherence to underlying tissues, and tumour ulceration were recorded. The date of first presentation and the growth rate of the tumours (defined as slow, medium or fast) were also recorded based upon the history (Perez Alenza et al., 1997; Queiroga et al., 2005) .
Mammary tissues were fixed in 10% formalin solution, embedded in paraffin, and then 5-µm histological sections were made and stained with haematoxylin and eosin (HE). Tumours were classified by size (in centimetres; wide-largehigh as diameter), according to the World Health Organization Clinical Staging System TNM (Owen, 1980) , as T 1 (< 3 cm), T 2 (3-5 cm) and T 3 (> 5 cm). In cases of multiple tumours, the largest one was used as the basis for classification.
Histological diagnosis was made on the basis of Goldschmidt's classification updated in recent years for CMTs as described by Goldschmidt et al. (2011) . Histological grading of mammary tumours was performed according to the Nottingham grading system, which belongs to the Elston-Ellis modification of the original Scarff-Bloom-Richardson (SBR) grading system and is popularly known as the contemporary European Breast Cancer Grading System. This system is based on three morphological features: tubule formation, mitotic index and nuclear pleomorphism (Simpson et al., 2000) . Scoring was obtained by screening 10 microscopic areas at ×400 magnification (High Power Field) at the periphery of the tumour. Up to 9 mitoses per 10 fields were scored 1 point, 10-19 mitoses 2 points, and 20 or more mitoses 3 points. At the same time, tubule formation was evaluated as follows: majority of the tumour (> 75%), moderate degree (10-75%) and little or none (< 10%). Depending on the nuclear polymorphism, the cell characteristics were scored as follows: small regular uniform cells: 1 point; moderate nuclear size and variation: 2 points; marked nuclear variation: 3 points. Overall, Grade 1 (G 1 ) represented well-differentiated tumours of 3-5 points, Grade 2 (G 2 ) moderately differentiated tumours of 6-7 points, and Grade 3 (G 3 ) poorly differentiated tumours of 8-9 points (Elston and Ellis, 1998; Simpson et al., 2000) . Additionally, in the differentiation of benign and malignant mammary tumours necrosis, invasion to periphery of tumour and lymphatics, and metastasis to regional lymph node were considered.
Total RNA isolation and reverse transcriptase (RT) reaction
Total RNA was isolated from the mammary tissue samples of 35 bitches using Trizol reagent (peqGOLD TriFastTM, Peqlab, Erlangen, Germany) and subsequently treated with RNase-free DNase I recombinant to prevent genomic DNA contaminations (DNase I; Roche Diagnostics, Germany) according to the manufacturer's instructions. RNA pellets were dissolved in 10-30 μl RNase-and DNase-free water, after which they were air-dried. The quantity and quality of total RNA were measured spectrophotometrically at 260 and 280 nm (NanoDrop 2000, Thermo Scientific). Isolated RNA was then stored at -80 °C. Equal amounts of RNA were used for reverse transcription. Complementary DNA (cDNA) was synthesised from 1 µg isolated RNA from each sample using the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Germany) according to the manufacturer's protocol, and synthesis reaction was carried out in an Eppendorf Mastercycler ep gradient S thermal cycler (Eppendorf, Hamburg, Germany). Samples were analysed in duplicates. cDNA products were kept at -20 °C.
Quantitative real-time PCR analysis
Real-time polymerase chain reaction (PCR) was performed using a LightCycler 480 instrument (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. The expression levels of the following genes were investigated: iNOS, COX-2 and VEGF. Beta actin was used as a housekeeping gene in order to normalise the mRNA expression levels of target genes. Probes and primers spanning the exon-exon junction were designed for each gene assay using the online UPL Assay Design Center (http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp). The sequences of the gene-specific primers and the UPL numbers are presented in Table 1 . A 2-μl volume of cDNA product was subjected to real-time PCR in a 10-μl total reaction mixture containing 2.5 μl of TaqMan Universal PCR Master Mix (Roche Diagnostics, Mannheim, Germany), 0.5 μl of sense and antisense primers, and 0.1 μl probe and template cDNA. Each sample was analysed in triplicate. Table 1 Gene-specific primer and probe sequences Gene Forward primer Reverse primer UPL probe no.
Statistical analysis
The data were analysed using LightCycler Software v 3.5 (Roche Diagnostics). Relative mRNA expression of iNOS, COX-2 and VEGF were determined using Relative Expression Software Tool 2008 (REST © ) (Pfaffl et al., 2002) . Correlations between the expression levels and the tumour grade were not determined because cycle threshold (Ct) values obtained from real-time PCR analysis resulted in real-time gene expression levels, and each animal had a single Ct value.
Results
Histopathological findings
Twenty-nine malignant mammary tumours and six benign mammary tumours were diagnosed ( Table 2 ). The commonest malignant tumour types in the study were carcinosarcoma (8/29; 27.58%) and mixed carcinoma (7/29; 24.13%). Clinically healthy mammary glands localised close to the gland with malignant tumour were evaluated and confirmed as non-neoplastic or healthy by histopathological evaluation. The maximum diameters of the malignant mammary tumours, histologic malignancy grades, tumour ulceration and necrosis, rate of growth and lymph node metastasis are presented in Table 3 .
The determination of histologic malignancy grade of the 29 dogs with malignant mammary tumours revealed that 12 had G 1 , 10 had G 2 and 7 had G 3 tumours. Of the 13 dogs (3 had G 1 , 7 had G 2 and 3 had G 3 ) in which histopathological lymph node examination was performed, lymph node metastasis was found in 1 dog with G 1 , 2 dogs with G 2 and 1 dog with G 3 . Tumour ulceration and necrosis were observed in 7 and 14 dogs, respectively (Table 3) . Table 2 Classification of canine mammary tumours (Goldschmidt et al., 2011) 
Expression of iNOS, COX-2 and VEGF in canine mammary tumours
The expression of iNOS, COX-2 and VEGF mRNA levels was significantly increased (P < 0.05) in both benign and malignant tumours compared to adjacent non-neoplastic mammary glands (Fig. 1) . In addition, the expressions were higher in malignant tumours than in benign tumours, although the difference was not statistically significant (P > 0.05). Table 3 presents the association between iNOS, COX-2 and VEGF expressions and clinicopathological features in malignant tumours. iNOS, COX-2 and VEGF expressions were associated with histological grade of malignancy and tumour growth rate (P < 0.05). The expressions of G 1 tumours were not statistically different when compared to G 2 (P > 0.05). On the other hand, the expression levels were higher in G 3 tumours than in G 1 tumours (P < 0.05) (Fig. 2) . There was no statistically significant association (P > 0.05) between iNOS, COX-2 and VEGF mRNA expressions and tumour size (Fig. 3) . 
Association of iNOS, COX-2 and VEGF expressions with clinicopathological parameters
Discussion
It has been reported that COX-2 level has prognostic significance and is increased in benign and malignant canine mammary tumours (Queiroga et al., 2010) . In addition, it has been established that COX-2 expression is significantly higher in malignant than in benign tumours in dogs (Dore et al., 2003) . However, COX-2 immunostaining was found to be altered in different histological types of benign tumours such as benign mixed tumours and tubular adenoma (Queiroga et al., 2007) . In the study of Queiroga et al. (2007) the expression of COX-2 was shown in 96% of benign tumours and in 100% of the malignant tumours, whereas ductal hyperplasia did not express COX-2. Similarly, in our study COX-2 expression was higher in malignant tumours than in benign tumours, although the difference was not statistically significant. This study also demonstrated that COX-2 expression was higher in benign and malignant tumours than in adjacent non-neoplastic mammary glands. Fig. 1 . Quantitative real-time PCR results showing COX-2, iNOS and VEGF mRNA expression levels in canine mammary tissue. Bars represent expression levels normalised to beta actin as the housekeeping gene and relative to non-neoplastic mammary glands (NMGs). * P < 0.05 relative to the NMGs group; mRNA: messenger RNA; PCR: polymerase chain reaction Fig. 2 . Quantitative real-time PCR results showing COX-2, iNOS and VEGF mRNA expression levels of histological malignancy in canine mammary tissue. Bars represent expression levels normalised to beta actin as the housekeeping gene and relative to G1 group. * P < 0.05 relative to the G1 group. mRNA: messenger RNA; PCR: polymerase chain reaction; Grade 1 (G1), well differentiated; Grade 2 (G2), moderately differentiated; Grade 3 (G3), poorly differentiated tumours COX-2 overexpression in human breast cancer and its relation to the presence of distant metastasis and poor prognosis have been reported previously (Denkert et al., 2003) . In canine mammary tumours, it has been revealed that COX-2 level is associated with larger tumour size, skin ulceration, adhesion to skin and underlying tissue, and more aggressive histological types (Queiroga et al., 2005; Guimaraes et al., 2014) . In the present study, COX-2 expression was higher in poorly differentiated than in well-differentiated tumours, suggesting that its higher expression might be related to the increased aggressiveness of malignant tumours.
It has been reported that COX-2 may be associated with angiogenesis because of the reduced adhesion of tumour cells to the extracellular matrix, angiogenesis and progress of metastasis in human breast cancer (Costa et al., 2002) . Several studies have shown that overexpression of COX-2 in tumour tissue is correlated with VEGF expression and microvessel density, and is a factor involved in the aggressiveness of canine malignant mammary tumours (Heller et al., 2005; Queiroga et al., 2011) . The present study has confirmed the results of Queiroga et al. (2011) that COX-2 and VEGF may be related to the increased aggressiveness of malignant tumours. The histological tumour grade is associated with the prognosis, whereas high-grade tumours are connected with low overall survival time in canine mammary carcinoma (Perez Alenza et al., 1997; Karayannopoulou et al., 2005) . Our study has revealed that the histological grade is related to the expression of iNOS, COX-2 and VEGF. Tascene et al. (2012) reported that serum nitric oxide level in dogs with mammary tumours is significantly higher than in healthy dogs. Recent studies have shown that iNOS expression in human colorectal and gallbladder cancer is associated with increased disease-specific fatality and/or malignancy degree (Niu et al., 2004; Zafirellis et al., 2010) . Moreover, it has also been determined that iNOS expression is related to different stages of human breast carcinoma (Ranganathan et al., 2016) . Our study is the first to determine the expression of iNOS by qRT-PCR analysis in malignant mammary tumours in dogs, and the findings of this work show that the expression of iNOS depends on tumour grade.
Perez Alenza et al. (1997) reported that dogs with larger tumours had short disease-free survival (DFS) and overall survival (OS). In addition, Philibert et al. (2003) found a significant difference in survival time depending on the size of canine mammary tumours, and dogs with tumours larger than 3 cm had a significantly shorter survival than dogs with tumours smaller than 3 cm. Additionally, Ferreira et al. (2009) revealed that larger tumours were mostly malignant and survival time was shorter in female dogs. It is known that increase in tumour size is not only associated with malignancy but also with metastasis to lymph nodes (Sorenmo et al., 2000) . Moreover, Queiroga et al. (2011) reported that tumour size was not associated with COX-2 and VEGF expression in canine malignant mammary tumours. Similarly, there was no statistically significant association between iNOS, COX-2 and VEGF mRNA expression levels and tumour size in our study. Karayannopoulou et al. (2005) found that the predictive value of histological grading of canine mammary carcinomas was associated with prognosis and that histological grading might be useful in managing post-surgical treatment. The results of our study revealed that iNOS, COX-2 and VEGF are overexpressed in canine mammary tumours compared to adjacent non-neoplastic mammary glands, and this may contribute to the increased aggressiveness of malignant tumours.
In conclusion, the higher expression of iNOS, COX-2 and VEGF mRNA levels in malignant tumours and the tendency of increase in these levels (particularly in grade 3 tumours) suggest that these parameters are involved in inducing aggressiveness in canine mammary tumours.
